Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Oncology in Practice
  3. Anti-Cancer Agents and Biological Therapy
  4. Targeting NTRK Gene Fusions
  5. Overview of Cancers with NTRK Gene Fusion
  6. TRK Inhibitors
  7. Repotrectinib

Repotrectinib

Previous Page Next Page

Clinical Development Programme

Clinical trials investigating repotrectinib are currently ongoing in adult and paediatric cancer patients and are exploiting its ability to interfere with NTRK as well as ALK and ROS signaling.

Summary of Ongoing Clinical Trials for Repotrectinib

Registry number

Name

Phase

Title

NCT03093116

TRIDENT-1

1/2

A study of repotrectinib (TPX-0005) in patients with advanced solid tumors harboring ALK, ROS1, or NTRK1-3 rearrangements

NCT04094610

-

1/2

A study of repotrectinib in paediatric and young adult subjects harboring ALK, ROS1, OR NTRK1-3 alterations

NCT05004116

-

1/2

A study of repotrectinib in combination with chemotherapy in children and young adults with solid tumour cancer

NCT05071183

-

1/2

A study of repotrectinib in combination with other anticancer therapies for the treatment of subjects with KRAS-mutant solid tumours

NCT04772235

TOTEM

1

Phase I study of repotrectinib and osimertinib in NSCLC patients

These data are current as of TBC (https://clinicaltrials.gov)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.